Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 April 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Characteristics and management of primary gastrointestinal non-Hodgkin's lymphoma

A uniform reporting system for primary gastrointestinal non-Hodgkin's lymphoma is needed to facilitate comparison of treatment results, according to research in the latest Journal of Clinical Oncology.

News image

fiogf49gjkf04

Researchers from Germany conducted two studies, in which they investigated the characteristics and management of patients with primary gastrointestinal non-Hodgkin's lymphomas (PGI NHL), between 1992 and 1996.

In the first, they obtained epidemiologic data and information on anatomic and histologic distribution, clinical features, and treatment results in 371 patients with PGI NHL.

Radiotherapy and chemotherapy were stratified according to histologic grading, stage, and whether surgery had been carried out or not.

Of the patients, 75% had gastric NHL. Within the intestine, the small bowel and the ileocecal region were involved in 9% and 7% of the cases, respectively. Multiple GI involvement was 6.5%.

Approximately 90% of the GI NHL were in stages IE/IIE.

Aggressive NHL accounted for the majority, with a distinguishable pattern in several sites.

40% of PGL were of low-grade mucosa-associated lymphatic tissue type. One third of large-cell lymphomas had low-grade components. Most intestinal NHL were germinal-center lymphomas.

In gastric and ileocecal lymphoma, event-free and overall survival were significantly higher, as compared with the small intestine or multiple GI involvement.

In PGL, localized disease was prognostic for both event-free and overall survival. However, histologic grade only influenced event-free survival significantly.

The authors commented that PGI NHL are heterogeneous diseases. The number of localized PGL allowed the investigators to conduct detailed analyses, although larger studies are needed for stages III and IV, and for intestinal NHL.

A uniform reporting system for PGI NHL, in terms of definitions, and histologic and staging classifications, is needed to facilitate comparison of treatment results, they concluded.

5-year survival rates after PGI NHL treatment:
Conservative treatment 84%
Conservative treatment plus surgery 85%
Journal of Clinical Oncology

In the second study, the team focused on the combined surgical and conservative treatment (CSCT) versus conservative treatment (CT) alone for localized gastric lymphoma.

Patients with low-grade PGL were treated with extended-field (EF) radiotherapy (30 Gy).

In case of residual tumor after surgery or in case of CT only (in stage IIE after 6 cycles of cyclophosphamide, vincristine, and prednisone), an additional boost of 10 Gy was given.

All patients with high-grade PGL were treated with 4 (stage IE) or 6 (stage IIE) cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone. This was followed by EF radiotherapy (stage IE) or involved-field (IF) radiotherapy (stage IIE).

Radiotherapy dosage corresponded to low-grade NHL.

A total of 106 patients had CT only. The survival rate after 5 years was found to be 84%. It was influenced neither by patients' characteristics nor by stage or histologic grade.

Some 79 patients had CSCT. Their survival rate was 82%.

The team found that complete resection of the tumor was prognostic for the overall survival, as compared with incomplete resection.

Dr Peter Koch, of Münster, Germany, concluded on behalf of the group, "Although the study was not randomized, a stomach-conserving approach may be favored."

J Clin Oncol 2001; 19 (18): 3861-83
20 September 2001

Go to top of page Email this page Email this page to a colleague

 20 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 20 April 2018 
Obesity and physical activity in diverticulosis
 20 April 2018 
Worldwide H.pylori prevalence
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 19 April 2018 
Fibrosis in patients with chronic hepatitis B
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA
 18 April 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 18 April 2018 
Hep C treatment for sustained virologic response
 18 April 2018 
Endoscopic necrosectomy reduces risk of death 
 17 April 2018 
Colorectal cancer screening and ethnic inequities
 17 April 2018 
Training programs should consider radiation education for advanced endoscopy fellows
 17 April 2018 
Aspirin and pancreatic cancer
 16 April 2018 
Surgery for colorectal polyps has increased 
 16 April 2018 
Advanced fibrosis can be ruled out in primary health care patients
 16 April 2018 
Antibiotic use and colorectal adenoma
 13 April 2018 
Colorectal cancer cell lines
 13 April 2018 
Infliximab and corticosteroid-free clinical remission in Crohn's
 13 April 2018 
Teduglutide for children with short bowel syndrome
 12 April 2018 
Prescriptions for opiate drugs amongst primary care patients with IBD
 12 April 2018 
Lower GI bleeding related to comorbidity
 12 April 2018 
non–Clostridium difficile bacterial infections in IBD
 11 April 2018 
Physician perception of IBD trial results
 11 April 2018 
Bile acid deficiency in IBS 
 11 April 2018 
Stem cell therapy for fistulas in Crohn's
 10 April 2018 
Overweight in childhood and type 2 diabetes
 10 April 2018 
immunoglobulin G associates with clinical features of IBD
 10 April 2018 
T-cells repertoires in celiac disease
 09 April 2018 
Biomarker tests for colorectal cancer screening
 09 April 2018 
Fecal transplantation in C. difficile infection and treatment outcome 
 09 April 2018 
No weigh-loss drug improved all cardiometabolic risk factors
 06 April 2018 
Colonoscopy and colorectal cancer mortality
 06 April 2018 
Eosinophilic esophagitis and health-related quality of life
 06 April 2018 
Microbiome in athletes vs sedentary subjects
 05 April 2018 
Laparoscopic Nissen fundoplication for GERD treatment
 05 April 2018 
Random biopsies for neoplasia in IBD
 05 April 2018 
Scoring system identifies cancer risk in Barrett's
 04 April 2018 
Alpha‐1 antitrypsin deficiency and liver disease
 04 April 2018 
PPI and risk of stroke
 04 April 2018 
Adjuvant chemotherapy for advanced colon cancer
 29 March 2018 
Prevention of metachronous gastric cancer
 29 March 2018 
Acute lower GI bleeding
 28 March 2018 
Decision aid used by IBD patients
 28 March 2018 
Transition for young adults with IBD
 28 March 2018 
Amitriptyline in functional dyspepsia
 27 March 2018 
Emergency department utilization for IBD 
 27 March 2018 
Management of hemorrhoids in the USA
 27 March 2018 
Adult ulcerative colitis
 26 March 2018 
Biological therapy response in IBD 
 26 March 2018 
Obesity and diverticulosis
 26 March 2018 
Practice guidelines for chronic constipation
 23 March 2018 
Health-related quality of life in eosinophilic esophagitis
 23 March 2018 
Genetics and chronic liver disease
 23 March 2018 
Global prevalence of H.pylori
 22 March 2018 
H. pyloris and gastric cancer
 22 March 2018 
Pancreatitis after IBS treatment 
 22 March 2018 
Mechanisms of action in patients with IBS
 21 March 2018 
Panel markers for early detection of colon cancer

 21 March 2018 
Blood test differentiates celiac disease
 21 March 2018 
Patient characteristics and colonoscopy preparation

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us